Biotech

Notify Therapeutics Secures €5M for the Development of a Non-Hormonal Fertility Treatment

Notify Therapeutics, a biotech company based in Denmark, has raised €5M in funding to advance the development of its innovative non-hormonal fertility treatment. The investment was made by Lundbeckfonden BioCapital and +ND Capital, highlighting their continued commitment to boosting Danish biotech and addressing pressing fertility issues. Founded from research by Professor Karin Lykke-Hartmann into female infertility, Notify Therapeutics is at the forefront…

Asieris’ Cevira, the First Non-Vaccine Investigational Product for Cervical HSIL, Has Achieved Its Primary Endpoint

In a stride forward for women’s health and cervical cancer prevention, Asieris Pharmaceuticals has declared the successful completion of its Phase III clinical trial for APL-1702 (Cevira), a non-surgical treatment aimed at cervical high-grade squamous intraepithelial lesions (HSIL). This significant milestone could shift the paradigm in treating this precancerous condition, offering a less invasive alternative to surgery, and may particularly benefit women…

NK:IO Secures £1.2M in Latest Funding Round to Advance Ovarian Cancer Treatment with Cell Therapy

NK:IO, a startup working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised an additional £1.2M in funding to advance its work. This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development. The £3.2M…

Celmatix and Aché Laboratórios Partner to Develop Melatonin Receptor Agonists for PCOS

Celmatix, a women’s health biotech company focused on ovarian biology, and Aché Laboratórios, a pharmaceutical company based in Brazil, have announced a collaboration to study a recently discovered melatonin receptor agonist. Their joint research aims to explore its potential applications in women’s health, with a primary focus on polycystic ovary syndrome (PCOS). This announcement follows Celmatix’s recent unveiling of its drug program,…

Mirvie Receives a $4.6M Grant from the Gates Foundation to Study Preeclampsia in Sub-Saharan Africa

Mirvie, a prenatal diagnostics company has received a $4.6M grant from the Bill & Melinda Gates Foundation to support the company’s efforts to predict unexpected pregnancy complications before they happen by revealing the underlying biology of each pregnancy for women on a global scale. Specifically, the funding will help launch study sites in Cameroon, Ghana, and Zambia to understand preeclampsia among pregnant…

Octave Bioscience Secures $30M for Its Precision Care Solution for Multiple Sclerosis

Autoimmune disease happens when the body’s natural defense system can’t tell the difference between own cells and foreign cells, causing the body to attack normal cells mistakenly. One of the most common autoimmune diseases is multiple sclerosis (in short MS), a potentially disabling disease of the central nervous system. In MS, the immune system attacks the protective sheath that covers nerve fibers and causes communication…

New Study: Zai Lab’s ZEJULA Maintenance Therapy Shows Promising Results in Advanced Ovarian Cancer Patients

JAMA Oncology has just published data from the Zai Lab‘s Phase 3 PRIME study, highlighting the positive outcomes of ZEJULA (niraparib) as a first-line maintenance therapy for Chinese patients with advanced ovarian cancer. The study reveals that ZEJULA significantly prolongs progression-free survival and reduces the risk of disease progression or death by 55%. These findings offer hope for improved outcomes in a…

New Study Validates Ziwig’s Saliva-based Endotest as Effective Alternative to Surgical Diagnosis for Endometriosis

French biotech company Ziwig has achieved a significant breakthrough in the field of endometriosis diagnosis with the validation of their Ziwig Endotest as a highly effective diagnostic tool. The study, published in the renowned New England Journal of Medicine (NEJM) Evidence, confirms the performance and reproducibility of Ziwig Endotest, boasting sensitivity and specificity rates exceeding 95%. This non-invasive test offers an alternative…